Qian Zhengzi, Song Zheng, Zhang Huilai, Wang Xianhuo, Zhao Jing, Wang Huaqing
Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tiyuanbei, Huanhuxi Road, Hexi District, Tianjin 300060, China.
Biomed Res Int. 2015;2015:606752. doi: 10.1155/2015/606752. Epub 2015 Mar 19.
T-cell lymphoma (TCL) is resistant to conventional chemotherapy. We retrospectively evaluated the therapeutic efficiency and toxicity of gemcitabine, navelbine, and doxorubicin (GND) in patients with refractory or relapsed TCL. From 2002 to 2012, 69 patients with refractory or relapsed TCL received GND treatment in our hospital. The treatment protocol comprised gemcitabine (800 mg/m(2), group 1; 1000 mg/m(2), group 2) on days 1 and 8, navelbine (25 mg/m(2)) on day 1, and doxorubicin (20 mg/m(2)) on day 1, repeated every 3 weeks. The overall response rate (ORR) was 65.2%. The median overall survival (OS) was 36 months. The 5-year estimated OS rate was 32.4%. The GND regimen was well tolerated. Subgroup analysis demonstrated that the ORR and CR for group 1 were similar. A longer median OS was observed for group 1. Significant difference in grades 3-4 toxicities was observed between groups 1 and 2 (P = 0.035). Our study indicated that gemcitabine (800 mg/m(2)) on days 1 and 8 every 21 days was favorable for pretreated TCL patients.
T细胞淋巴瘤（TCL）对传统化疗具有耐药性。我们回顾性评估了吉西他滨、长春瑞滨和阿霉素（GND）对难治性或复发性TCL患者的治疗效果及毒性。2002年至2012年，69例难治性或复发性TCL患者在我院接受了GND治疗。治疗方案为第1天和第8天使用吉西他滨（800mg/m²，第1组；1000mg/m²，第2组），第1天使用长春瑞滨（25mg/m²），第1天使用阿霉素（20mg/m²），每3周重复一次。总缓解率（ORR）为65.2%。中位总生存期（OS）为36个月。5年估计总生存率为32.4%。GND方案耐受性良好。亚组分析表明，第1组的ORR和CR相似。第1组观察到更长的中位OS。第1组和第2组在3-4级毒性方面存在显著差异（P = 0.035）。我们的研究表明，每21天的第1天和第8天使用吉西他滨（800mg/m²）对预处理的TCL患者有利。
